CORE--COLON ONCOLOGY

核心--结肠肿瘤学

• 批准号: 3773505
• 负责人: HOWARD HOCHSTER
• 金额: --
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3773505
• 关键词: antineoplastics; biomedical facility; cancer information system; cancer registry /resource; cell bank /registry; colon neoplasms; drug screening /evaluation; human subject

CORE FACILITY-COLON ONCOLOGY is included in the project entitled: 'DNA Topoisomerase I-Targeted Therapy of Colonic Cancer'. A tissue depository ('Human Tissue Band"), which is part of the facility, is essential for the following aims of the Proposal: 1. To select patients with adenocarcinoma of the colon and obtain their pathologic and normal colonic tissues for laboratory studies. 2. To maintain the Human Tissue Bank as a source of clinical material for research on molecular, cellular and tumor biology of DNA topoisomerase I. 3. To organize a patient data base, which will be used to correlate laboratory and clinical findings. This part of the project has been initiated, and the results of investigations are reported under Preliminary Studies. The overall objectives will be met by the end of the 02 year of support. In year 02- 03, two additional objectives will be accomplished: 4. To prepare the Investigational New Drug (IND) application to the US Food and Drug Administration. The application will be based on Project studies of one or several leading analogs, as well as on toxicology and pharmacology research done independently outside this Project. 5. To prepare a Phase-I protocol for initial clinical research of leading analog(s) discovered in the Project.

核心设施-结肠肿瘤学包含在名为“DNA”的项目中 结肠癌的拓扑异构酶 I 靶向治疗'。 组织存放处 （“人体组织带”）是该设施的一部分，对于 该提案的目标如下： 1. 选择结肠腺癌患者并获取其 用于实验室研究的病理和正常结肠组织。 2. 维持人体组织库作为临床材料的来源 DNA拓扑异构酶I的分子、细胞和肿瘤生物学研究。 3. 建立患者数据库，用于关联 实验室和临床结果。 该部分项目已启动，并取得成果 调查报告在初步研究中。 整体 目标将在第二年支持结束时实现。 02年- 03，将实现另外两个目标： 4. 准备向美国食品药品监管局提交的新药研究（IND）申请 和药品管理局。 该申请将基于项目研究 一种或几种主要类似物的研究，以及毒理学和 在本项目之外独立完成的药理学研究。 5. 准备领先的临床研究的I期方案 项目中发现的类似物。